Epigenetic targeting of histone deacetylase: therapeutic potential in Parkinson's disease?
about
Proteome-wide lysine acetylation in cortical astrocytes and alterations that occur during infection with brain parasite Toxoplasma gondiiEpigenetics and Triplet-Repeat Neurological DiseasesEpigenetic Research of Neurodegenerative Disorders Using Patient iPSC-Based ModelsComputational Modelling Approaches on Epigenetic Factors in Neurodegenerative and Autoimmune Diseases and Their Mechanistic AnalysisEpigenetics of Alzheimer's disease and frontotemporal dementiaNew Insights for Oxidative Stress and Diabetes MellitusGDNF-based therapies, GDNF-producing interneurons, and trophic support of the dopaminergic nigrostriatal pathway. Implications for Parkinson's diseaseDrug delivery systems, CNS protection, and the blood brain barrierConsiderations on the role of environmental toxins in idiopathic Parkinson's disease pathophysiologyMicrobiota in anorexia nervosa: The triangle between bacterial species, metabolites and psychological tests.The histone deacetylase inhibitor sodium butyrate decreases excessive ethanol intake in dependent animals.The gut microbiome and the brain.Complex network-driven view of genomic mechanisms underlying Parkinson's disease: analyses in dorsal motor vagal nucleus, locus coeruleus, and substantia nigraTherapeutic perspectives of epigenetically active nutrients.Histone acetyltransferase inhibitor C646 reverses epithelial to mesenchymal transition of human peritoneal mesothelial cells via blocking TGF-β1/Smad3 signaling pathway in vitroContra-Directional Expression of Serum Homocysteine and Uric Acid as Important Biomarkers of Multiple System Atrophy Severity: A Cross-Sectional Study.Neurorestoration induced by the HDAC inhibitor sodium valproate in the lactacystin model of Parkinson's is associated with histone acetylation and up-regulation of neurotrophic factors.The Class I-Specific HDAC Inhibitor MS-275 Decreases Motivation to Consume Alcohol and Relapse in Heavy Drinking Rats.General Base-General Acid Catalysis in Human Histone Deacetylase 8.Regulation of Histone Acetylation by Autophagy in Parkinson DiseaseAssociated degeneration of ventral tegmental area dopaminergic neurons in the rat nigrostriatal lactacystin model of parkinsonism and their neuroprotection by valproateIschemic preconditioning, retinal neuroprotection and histone deacetylase activities.Epigenetic findings in autism: new perspectives for therapy.The Epigenome as a therapeutic target for Parkinson's disease.Involvement of HDAC1 and HDAC3 in the Pathology of Polyglutamine Disorders: Therapeutic Implications for Selective HDAC1/HDAC3 Inhibitors.The potential of epigenetic therapies in neurodegenerative diseasesTargeting histone deacetylases: a novel approach in Parkinson's disease.Epigenetic mechanisms in neurological and neurodegenerative diseases.Epigenetic Treatment of Neurodegenerative Disorders: Alzheimer and Parkinson Diseases.Epigenetic Treatment of Neuropsychiatric Disorders: Autism and Schizophrenia.A Small Molecule Activator of p300/CBP Histone Acetyltransferase Promotes Survival and Neurite Growth in a Cellular Model of Parkinson's Disease.ALS and FTD: an epigenetic perspective.The discovery of a highly selective 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one SIRT2 inhibitor that is neuroprotective in an in vitro Parkinson's disease model.Deregulation of α-synuclein in Parkinson's disease: Insight from epigenetic structure and transcriptional regulation of SNCA.A Drosophila model of Huntington disease-like 2 exhibits nuclear toxicity and distinct pathogenic mechanisms from Huntington disease.Bioprotective carnitinoids: lipoic acid, butyrate, and mitochondria-targeting to treat radiation injury: mitochondrial drugs come of age.Comprehensive profiling of lysine acetylation suggests the widespread function is regulated by protein acetylation in the silkworm, Bombyx mori.Neuroprotective role of thymoquinone against 1-methyl-4-phenylpyridinium-induced dopaminergic cell death in primary mesencephalic cell culture.Sulforaphane epigenetically enhances neuronal BDNF expression and TrkB signaling pathways.Pathological histone acetylation in Parkinson's disease: Neuroprotection and inhibition of microglial activation through SIRT 2 inhibition.
P2860
Q22255525-08D5D103-A2C5-46D3-875C-FE0A29033817Q26770705-EBB817BE-6066-4381-8D65-56A4517FC4EDQ26772307-ADCE7AB9-39F7-4CE1-AA73-554E5F0F9A9CQ26774368-56016BDA-8E37-4D55-B4AB-EEC28188A2A4Q27010153-F10CADBE-D111-4D6A-836C-771455002990Q28080679-4D3DA559-2A10-427B-99DB-A5A59B44740EQ28088320-9242FA53-A679-43AB-9AE9-4D1C5B672D5CQ30432845-0A52C6E7-37CD-4DE1-AEF8-67CFC9B56EB1Q33603777-D0D4BEDD-4AA7-4BCB-92CB-42E2C4F0E05BQ33821872-655CAB5B-0654-49D7-836A-686737B3523FQ34429848-4E3CCB16-B93C-46E7-BBF0-FED434637A18Q34652493-2BD16947-5028-45BE-8439-F5A6D0BAC142Q34667486-B2240AD6-748E-4076-A5E0-8CB895B1D5F5Q35631468-35065956-A3DE-44C3-8106-502A86E0C145Q35632155-B324AE9C-97BA-41A9-9CFC-C51AD88CF83FQ35820242-201823E7-11EA-4FFE-9E40-8B4FDE53E324Q35978159-B2396F9E-14CF-4FCF-BD82-051E8DA6B34DQ36077200-E4D1ABAC-AD4B-48C0-81AA-68C1715DDC97Q36563651-6A5AD6D9-5C3E-44B2-A302-A8D68AD1ACDEQ36574016-A67109F1-8A55-4279-BAE7-611E183A7229Q36587423-3E551EFA-0F62-4E71-BFD4-452D2155C3DBQ36971583-4C5DFC60-185E-4EA3-ADF2-AAA0F1FF2F20Q37237028-60B510B8-A52B-4A78-B33A-835874A04E1CQ37548331-41CC3928-81D5-4094-B8A0-A2DB87D5199DQ38215303-428559A4-302A-432C-B556-28EE7A650BC3Q38234971-B29C7037-869C-4570-B5DD-F9F86A12483CQ38361065-B4E7B7B0-4D04-4444-A360-3F1D4C8F73C4Q38379396-5E438FD2-0943-4876-83E0-2170804D550EQ38742951-D1D44E21-7E58-4A08-8A98-6B2CA099ACB8Q38743021-A8D31C49-7F08-4B43-B749-5DBCB8ACA278Q38766912-90CB148A-2F51-4F6A-A910-1697A4581019Q38860456-E2BE9406-FB3E-438B-9801-1D08924E2DC5Q38940509-407A8A6F-9D01-4ADE-8158-4D264C5899D7Q39264615-69D7F8CF-E768-4391-81F2-D229886FCA5AQ39732144-E013A202-C904-409B-B115-9B4BE097BDFAQ41953858-7A595DE3-7A1D-47C5-A668-469812D68CC6Q41997892-5252D79F-EA97-4A8C-88E2-6F37781EE808Q43067393-934412F5-36DA-4CD7-B5EB-4AB2201C44B0Q43650001-1372D238-9678-4F56-9EEB-014A335CACB3Q47259835-3AC0CB88-A186-4332-9F54-63306BDAA84E
P2860
Epigenetic targeting of histone deacetylase: therapeutic potential in Parkinson's disease?
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Epigenetic targeting of histon ...... ential in Parkinson's disease?
@en
type
label
Epigenetic targeting of histon ...... ential in Parkinson's disease?
@en
prefLabel
Epigenetic targeting of histon ...... ential in Parkinson's disease?
@en
P1476
Epigenetic targeting of histon ...... ential in Parkinson's disease?
@en
P2093
David T Dexter
P356
10.1016/J.PHARMTHERA.2013.05.010
P50
P577
2013-05-24T00:00:00Z